capping protein regulator and myosin 1 linker 2Genealiases: CARMIL2b · IMD58 · LRRC16C · RLTPR
Q-omics provides the consensus-scored CARMIL2 profile across patient tissues and cancer cell-line models. CARMIL2 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CARMIL2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CARMIL2 protein abundance shows 21,384 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where CARMIL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CARMIL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CARMIL2 survival associations across molecular data types. CARMIL2 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CARMIL2 RNA expression–survival associations across cancer types. High CARMIL2 expression shows unfavorable associations in KIRP, MESO and KIRC, but favorable associations in HNSC, SKCM and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CARMIL2 RNA expression.
This table summarizes CARMIL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CARMIL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CARMIL2 shows higher tumor expression in KIRC, STAD, LUAD, BRCA, UCEC and HNSC. The KIRC box plot shows higher CARMIL2 RNA expression in tumor versus normal tissue (log2 FC = +0.775, t-test p < 0.001).
This table shows molecular features associated with CARMIL2 in patient tissues and cancer cell lines. In patient samples, CARMIL2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CARMIL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
